Pediatric Oncology | Specialty

The pediatric oncology condition center is a comprehensive resource for clinical news and expert insights on pediatric oncology. Read more at OncLive.

Mirdametinib Earns Positive CHMP Opinion for NF1-Associated Plexiform Neurofibromas

May 23rd 2025

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

Treatment Trends and Ongoing Research in Pediatric Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss ongoing research in pediatric acute leukemia.

Factors to Consider in Pediatric Acute Leukemia Management

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss key factors for the management of pediatric acute leukemia.

Breaking Down Treatment Expectations With Revumenib in Pediatric KMT2A+ R/R Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss treatment expectations with revumenib in pediatric relapsed/refractory acute leukemia.

Integrating 25-mg Tablets of Revumenib Into Pediatric R/R Acute Leukemia Management

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the use of 25-mg tablets of revumenib in pediatric KMT2A-translocated relapsed/refractory acute leukemia.

When to Test for KMT2A Rearrangements and Other Alterations in Pediatric Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the optimal timing of testing for KMT2A rearrangements in pediatric acute leukemia.

Implications of the FDA Approval of Revumenib in KMT2A+ R/R Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, on the significance of the FDA approval of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Current Treatment Strategies in Pediatric R/R AML and ALL

May 21st 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss current treatment trends in pediatric relapsed/refractory acute leukemia.

Updated NCCN Guidelines Recommend Naxitamab in High-Risk Neuroblastoma

May 7th 2025

The NCCN guidelines now recommend a naxitamab-based regimen for high-risk neuroblastoma.

FDA Approves Larotrectinib for NTRK-Positive Solid Tumors

April 10th 2025

The FDA has granted full approval to larotrectinib for select patients with solid tumors harboring a NTRK gene fusion.

AYA Cancer Awareness Week: Patient Support, Multidisciplinary Care Are Key for Management of NETs

April 4th 2025

Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.

Researchers Find Inherited Genetic Condition Raises Risk of Developing Two Rare Pediatric Cancers

March 6th 2025

Roswell Park’s Dr Kenan Onel leads large international team that sheds light on pineoblastoma and Wilms tumor.

Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber

February 21st 2025

Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.

Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

FDA Approves Mirdametinib for NF1-Associated Plexiform Neurofibromas

February 11th 2025

The FDA has approved mirdametinib for patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas.

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

February 3rd 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS

January 24th 2025

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

December 18th 2024

The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.

Bicistronic CD19/CD22-Directed CAR T-Cell Therapy Is Safe, Elicits Durable Responses in Pediatric R/R B-ALL

December 7th 2024

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.